- Drug Pipelines
- January 2019
- 40 Pages
Global
From €1450EUR$1,500USD£1,246GBP
- Report
- August 2022
Global
From €4350EUR$4,500USD£3,739GBP
- Report
- July 2018
- 765 Pages
Global
From €21268EUR$22,000USD£18,280GBP
- Report
- February 2022
- 120 Pages
United States
From €2417EUR$2,500USD£2,077GBP
- Report
- April 2022
- 120 Pages
Global
From €2417EUR$2,500USD£2,077GBP
- Report
- June 2021
- 120 Pages
Global
From €2417EUR$2,500USD£2,077GBP
- Report
- August 2022
United States
From €1875EUR$1,940USD£1,612GBP
- Report
- August 2022
Global
From €1150EUR$1,190USD£989GBP
- Report
- February 2021
Global
From €2861EUR$2,960USD£2,459GBP
- Report
- August 2021
Global
From €3857EUR$3,990USD£3,315GBP
- Report
- August 2021
Europe
From €3306EUR$3,420USD£2,842GBP
- Drug Pipelines
- April 2023
- 117 Pages
Global
From €10629EUR$10,995USD£9,136GBP
- Report
- January 2023
- 1452 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Clinical Trials
- August 2021
- 1375 Pages
Global
From €2417EUR$2,500USD£2,077GBP
- Clinical Trials
- February 2021
- 1432 Pages
Global
From €2417EUR$2,500USD£2,077GBP
- Report
- December 2019
- 356 Pages
Global
From €10629EUR$10,995USD£9,136GBP
- Report
- November 2019
- 38 Pages
Global
From €3862EUR$3,995USD£3,319GBP
- Report
- July 2018
- 52 Pages
Global
From €3379EUR$3,495USD£2,904GBP
- Drug Pipelines
- June 2020
- 1114 Pages
Global
From €2417EUR$2,500USD£2,077GBP
- Report
- February 2020
- 40 Pages
Saudi Arabia
From €2509EUR$2,595USD£2,156GBP
The Multiple Sclerosis (MS) Drug market is a subset of the Central Nervous System (CNS) Drugs market. MS is a chronic, progressive neurological disorder that affects the central nervous system, causing a wide range of physical and mental symptoms. MS drugs are used to reduce the frequency and severity of MS relapses, slow the progression of the disease, and improve the quality of life of those affected.
MS drugs are typically divided into two categories: disease-modifying therapies (DMTs) and symptomatic therapies. DMTs are used to slow the progression of the disease, while symptomatic therapies are used to manage the symptoms of MS. Common DMTs include interferon beta, glatiramer acetate, fingolimod, and natalizumab. Common symptomatic therapies include muscle relaxants, antispasmodics, and antidepressants.
The MS Drug market is highly competitive, with a number of major pharmaceutical companies competing for market share. Some of the major players in the market include Biogen, Novartis, Merck, Sanofi, and Teva Pharmaceuticals. Show Less Read more